Interventions for Silent Brain Infarction and Perioperative Neurocognitive Dysfunction in Cardiovascular Surgery
Launched by CHINESE ACADEMY OF MEDICAL SCIENCES, FUWAI HOSPITAL · Jun 24, 2025
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new approach called the NeuroFirst strategy, which aims to protect the brain during heart surgery. The goal is to see if this approach can reduce the chances of silent brain infarctions (small strokes that don’t cause obvious symptoms) and problems with thinking or memory that sometimes happen after surgery. The NeuroFirst strategy involves carefully monitoring and controlling things like blood pressure, brain activity, oxygen levels in the brain, and body temperature during the surgery. Researchers want to find out if this method is better and just as safe as the usual care given during heart surgery.
Adults aged 60 and older who are having planned heart surgery with the use of a heart-lung machine may be eligible to join this study. Participants will be randomly assigned to either the NeuroFirst group or to receive standard care. Everyone will have brain scans (MRI) and tests to check thinking and memory abilities before and after surgery, with follow-up visits for up to a year. Some people, such as those who can’t have an MRI, are pregnant, or have certain health issues, won’t be able to join. This study is not yet recruiting, but it hopes to learn if this new brain protection method can help improve recovery for older adults undergoing heart surgery.
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • Male or female adult patients aged 60 years or older
- • Receiving elective cardiovascular surgery with cardiopulmonary bypass
- • Written Informed consent provided
- Exclusion criteria:
- • Contraindication to MRI scanning
- • Not suitable for receiving interventions to achieve NeuroFirst target bundle
- • Unable to receive neuro-cognitive evaluation due to language, vision, or hearing impairments
- • Breastfeeding or pregnancy
- • Terminal illness with a life expectancy of less than 3 months
- • Mental or legal disability
- • current enrollment in other interventional study
About Chinese Academy Of Medical Sciences, Fuwai Hospital
The Chinese Academy of Medical Sciences (CAMS) Fuwai Hospital is a leading institution in cardiovascular research and healthcare in China, renowned for its commitment to advancing medical knowledge and improving patient care. As a major clinical trial sponsor, Fuwai Hospital focuses on innovative therapies and interventions, leveraging its extensive resources and expertise in cardiology and related fields. The institution fosters collaboration among multidisciplinary teams of researchers and healthcare professionals, aiming to translate scientific discoveries into clinical applications effectively. With a robust regulatory framework and a dedication to ethical research practices, CAMS Fuwai Hospital plays a pivotal role in addressing critical health challenges and enhancing the quality of life for patients both nationally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Beijing, Beijing, China
Beijing, Beijing, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported